Literature DB >> 19834064

Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.

Yukiko Doi1, Tetsuya Mizuno, Yuki Maki, Shijie Jin, Hiroyuki Mizoguchi, Masayoshi Ikeyama, Minoru Doi, Makoto Michikawa, Hideyuki Takeuchi, Akio Suzumura.   

Abstract

Soluble oligomeric amyloid beta (oAbeta) 1-42 causes synaptic dysfunction and neuronal injury in Alzheimer's disease (AD). Although accumulation of microglia around senile plaques is a hallmark of AD pathology, the role of microglia in oAbeta1-42 neurotoxicity is not fully understood. Here, we showed that oAbeta but not fibrillar Abeta was neurotoxic, and microglia activated with unmethylated DNA CpG motif (CpG), a ligand for Toll-like receptor 9, attenuated oAbeta1-42 neurotoxicity in primary neuron-microglia co-cultures. CpG enhanced microglial clearance of oAbeta1-42 and induced higher levels of the antioxidant enzyme heme oxygenase-1 in microglia without producing neurotoxic molecules such as nitric oxide and glutamate. Among subclasses of CpGs, class B and class C activated microglia to promote neuroprotection. Moreover, intracerebroventricular administration of CpG ameliorated both the cognitive impairments induced by oAbeta1-42 and the impairment of associative learning in Tg2576 mouse model of AD. We propose that CpG may be an effective therapeutic strategy for limiting oAbeta1-42 neurotoxicity in AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834064      PMCID: PMC2774075          DOI: 10.2353/ajpath.2009.090418

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.

Authors:  Matthew Townsend; Tapan Mehta; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2007-09-13       Impact factor: 5.157

2.  Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.

Authors:  Henrieta Scholtzova; Richard J Kascsak; Kristyn A Bates; Allal Boutajangout; Daniel J Kerr; Harry C Meeker; Pankaj D Mehta; Daryl S Spinner; Thomas Wisniewski
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

3.  Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease.

Authors:  M Takahashi; S Doré; C D Ferris; T Tomita; A Sawa; H Wolosker; D R Borchelt; T Iwatsubo; S H Kim; G Thinakaran; S S Sisodia; S H Snyder
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

4.  Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Karine L Richard; Mohammed Filali; Paul Préfontaine; Serge Rivest
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

5.  Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice.

Authors:  Hiroyuki Mizoguchi; Kazuhiro Takuma; Ayumi Fukakusa; Yukio Ito; Akiko Nakatani; Daisuke Ibi; Hyoung-Chun Kim; Kiyofumi Yamada
Journal:  Psychopharmacology (Berl)       Date:  2007-10-02       Impact factor: 4.530

6.  Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis.

Authors:  Shweta Mandrekar; Qingguang Jiang; C Y Daniel Lee; Jessica Koenigsknecht-Talboo; David M Holtzman; Gary E Landreth
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

7.  Toll-like receptor 9: a new target of ischemic preconditioning in the brain.

Authors:  Susan L Stevens; Thomas M P Ciesielski; Brenda J Marsh; Tao Yang; Delfina S Homen; Jo-Lynn Boule; Nikola S Lessov; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2008-01-09       Impact factor: 6.200

8.  Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms.

Authors:  Marlen Knobloch; Mélissa Farinelli; Uwe Konietzko; Roger M Nitsch; Isabelle M Mansuy
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

9.  Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.

Authors:  Melanie Meyer-Luehmann; Tara L Spires-Jones; Claudia Prada; Monica Garcia-Alloza; Alix de Calignon; Anete Rozkalne; Jessica Koenigsknecht-Talboo; David M Holtzman; Brian J Bacskai; Bradley T Hyman
Journal:  Nature       Date:  2008-02-07       Impact factor: 49.962

10.  Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.

Authors:  Akihiro Mouri; Yukihiro Noda; Hideo Hara; Hiroyuki Mizoguchi; Takeshi Tabira; Toshitaka Nabeshima
Journal:  FASEB J       Date:  2007-03-06       Impact factor: 5.191

View more
  65 in total

1.  Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease.

Authors:  Jean-Philippe Michaud; Karine L Richard; Serge Rivest
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression.

Authors:  Mariko Noda; Yukiko Doi; Jianfeng Liang; Jun Kawanokuchi; Yoshifumi Sonobe; Hideyuki Takeuchi; Tetsuya Mizuno; Akio Suzumura
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 3.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 4.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 5.  Toll-like receptor signaling in neural plasticity and disease.

Authors:  Eitan Okun; Kathleen J Griffioen; Mark P Mattson
Journal:  Trends Neurosci       Date:  2011-03-16       Impact factor: 13.837

Review 6.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

7.  Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease?

Authors:  Maria Clara Selles; Juliana Tiemi Sato Fortuna; Luís Eduardo Santos
Journal:  J Neurosci       Date:  2017-05-10       Impact factor: 6.167

Review 8.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 9.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

10.  Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype.

Authors:  Konstantin Dirscherl; Marcus Karlstetter; Stefanie Ebert; Dominik Kraus; Julia Hlawatsch; Yana Walczak; Christoph Moehle; Rudolf Fuchshofer; Thomas Langmann
Journal:  J Neuroinflammation       Date:  2010-01-14       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.